QinetiQ wins technical services tender for US Army DEVCOM
QinetiQ has won a technical services contract with the US Army. (Photo: US Army/Sgt Robert Whitlow)
QinetiQ announced on 9 August that it has won a new technical services contract worth up to $45 million from the US Army following a competitive tender.
The deal will see QinetiQ provide services for the C5ISR division within US Army Development Command (DEVCOM) at the Fort Belvoir Prototyping Integration Facility.
QinetiQ will initially execute the contract in a 12-month base period of performance, followed by four 12-month options. It will provide technical services for system development, fabrication, sensor and system integration, prototyping of multi-function sensor suites, and technology assessment efforts.
The company stated that the new contract will help to deliver ‘organic growth in the US’. QinetiQ recently also announced the acquisition of US-based Avantus Federal LLC.
More from Defence Notes
-
UK releases security strategy and plans for future defence spending boost
The UK’s National Security Strategy brings together the recently released Strategic Defence Review (SDR), Strategic Security Review, AUKUS Review and Industrial and Trade Strategies. At the same time, the UK made a commitment to reach defence spending of 5% of GDP by 2035 and Germany committed to 3.5% by 2029.
-
Pentagon’s FY26 defence budget proposal is $130 billion more than US Congress plans to provide
The House Committee on Appropriations approved a FY2026 bill reducing investments in main defence programmes.
-
What role could holographic and 3D capabilities play in the warfare of tomorrow
Holographic and 3D technologies have been lauded by some for their ability to provide technical and operational advantages for military training and planning. But is the hype truly justified?
-
Unfolding the Golden Dome for America: Seven things you should know about the programme
Shephard talked to multiple experts about the most pressing concerns and considerations regarding the air defence system advocated by President Trump.